// App-Quantinova.ai

: A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.

Researchers

Presenter

  • Kazufumi Kobayashi

Principal Investigators

  • Susumu Maruta

  • Tomomi Okubo

  • Michihisa Moriguchi

  • Hiroaki Kanzaki

  • Keisuke Koroki

  • Naoya Kanogawa

  • Yuki Shiko

  • Yosuke Inaba

  • Kazuyoshi Nakamura

  • Ryosaku Azemoto

  • Kenji Ito

  • Shinichiro Okabe

  • Masanori Atsukawa

  • Ei Itobayashi

  • Masafumi Ikeda

  • Naoki Morimoto

  • Yoshito Itoh

  • Naoya Kato

Medical Centers

  • Department of Gastroenterology, Kimitsu Chuo Hospital, Kisarazu, Japan

  • Department of Medical Oncology,Osaki Citizen Hospital, Osaki-Shi, Japan

  • Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

  • Department of Medical Oncology,Osaki Citizen Hospital, Osaki-Shi, Japan

  • Department of Medical Oncology,Osaki Citizen Hospital, Osaki-Shi, Japan

  • Jichi Medical University, Tochigi, Japan

  • Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan

  • Department of Gastroenterology, Chiba University Graduate School of Medicine, Chiba-shi, Chiba, Japan

  • Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan

  • Kyoto Prefectural University of Medicine, Suita, Japan

  • Department of Gastroenterology, National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan

  • Kyoto Prefectual University, Kyoto, Japan

  • Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan

  • Chiba University, Graduate School of Medicine, Department of Gastroenterology, Chiba-Shi Chuo-Ku, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Liver cancer

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved